anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Vomiting is one of the most common adverse events of chemotherapy. The purpose of this study was to systematically review the clinical efficacy of acupoint injection of metoclopramide in the treatment of post-chemotherapy vomiting.
METHODS: We searched 4 general English databases and 4 conventional Chinese databases, all with a time frame from database creation to December 2022. The retrieved clinical trials of acupoint injection of metoclopramide for post-chemotherapy vomiting were then subjected to meta-analysis and trial sequential analysis.
RESULTS: A total of 12 studies were included, with a total sample size of 965 cases. Meta-analysis showed that acupoint injection of metoclopramide was effective in improving anti-vomiting effective rate [odds ratio = 5.67, 95% confidence interval = (3.80,8.47), P < .00001] compared with intramuscular/intravenous injection, and trial sequential analysis showed that this benefit was conclusive. Subgroup analysis demonstrated that acupoint injection significantly improved the anti-vomiting effective rate at doses of 10 mg qd, 20 mg qd, and 30 mg qd, as well as at durations of 1 day and 5 days. Subgroup analysis also indicated that injection at the Zusanli acupoint significantly increased the anti-vomiting effective rate, while injection at the Neiguan acupoint had an anti-vomiting effective rate comparable to that of the control group. Harbord regression showed no significant publication bias (P = .730).
CONCLUSION: Acupoint injection of metoclopramide for post-chemotherapy vomiting is more effective than intramuscular and intravenous injections and is not limited by dose or duration of treatment, which may be the preferred way of administration.
Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
Nutritional status may be important in achieving optimal physical performance. There is evidence of significant improvements in physical fitness, aerobic capacity and anaerobic threshold of children and adolescents with nutritional intervention, albeit in children with initial sub-optimal nutritional status. This may be of particular relevance in developing countries like India, where there is limited data on physical fitness and a wide-spread prevalence of concurrent micronutrient deficiencies even in apparently normal school age children. The present study therefore, is designed to assess the effect of a nutritional supplement on the physical performance measures of school going children. This is a randomized, double blind placebo-controlled study of three treatment groups (1 test, 1 positive control (placebo) and 1 'no intervention') conducted in equal numbers of male or female children \[ages 7-11\] attending day schools in Bangalore. Subjects in the intervention (test and positive control) groups will receive study treatments (fortified or un-fortified nutritional powder) once a day for 4 months. The treatments will be administered under supervision on all school working days; for the weekend and other holidays, sachets will be provided for home consumption. At baseline and 4months, physical performance tests will be administered and blood sample drawn to assess nutritional status. Other selected outcome measures such as nutrition status and muscle strength/ endurance will also be assessed. It is hypothesized that after 4 months of intervention, children consuming fortified nutritional powder will have statistically significant improvements in physical performance/ fitness measures as compared to the two control groups.
Malaria is among the leading infectious causes of death in many of the world s poorest countries. This parasitic mosquito-borne illness produces massive hemolysis in many infected human hosts. While much is known about parasite replication and cytoadherence, very little is known about the impact of hemolysis per se on vascular tone and endothelial function. Crossing a number of medical disciplines beyond the scope of malaria, intriguing new research on inherited hemolytic disorders such as sickle cell disease (SCD) provides clues to pathogenic mechanisms that may be relevant to malaria. Dr. Gladwin (NHLBI) and colleagues have characterized a mechanism of disease, hemolysis-associated endothelial dysfunction, in which red blood cell hemoglobin spills into plasma and reacts with and oxidatively destroys nitric oxide (NO). Additionally, erythrocyte arginase I is released into plasma and catabolizes arginine, the substrate for endothelial NO synthesis. As a result, the profound reduction in NO bioavailability produces vasomotor instability, oxidant stress, inflammation, endothelial adhesion molecule expression, activation of tissue factor, and platelet aggregation. Consistent with shared mechanisms, these same pathways are found to be activated during malarial infection. Chronic hemolysis in hemoglobinopathies also leads to a disease syndrome, hemolysis associated pulmonary hypertension, which develops in all chronic hereditary and acquired hemolytic conditions and is associated with excessive morbidity and mortality. Despite the recent appreciation of these mechanisms, not one study can be found in the literature evaluating pulmonary hypertension in human malaria.

This protocol therefore aims to evaluate mechanisms governing interrelationships among malaria, intravascular hemolysis, NO bioavailability, endothelial function, pulmonary hypertension, and evolutionarily selected host polymorphisms that regulate the host response to hemolysis. We will correlate our clinical observations in the field with laboratory assays of hemolysis and nitric oxide bioavailability related to scavenging by cell-free hemoglobin and arginine catabolism. Using a candidate gene approach, we will identify and selectively characterize polymorphisms in genes important for endothelial function, vascular inflammation and disease phenotype. Finally, the characterization of this mechanism in malaria may catalyze the development of novel therapies targeting this pathway, such as sodium nitrite, inhaled nitric oxide gas, and/or recombinant haptoglobin infusions.

This international collaboration between scientists at the NIH, University of Bamako, and Tulane University will provide an exclusive opportunity for the rapid transfer of appropriate technology and expertise relevant to the provision of the highest quality care to malaria patients in Mali and the world.
PURPOSE: The relationship between vitamin intake and cancer risk in the chronic kidney disease (CKD) population is unknown. For this reason, we investigated the relationship between dietary vitamin intake and cancer risk in CKD patients and looked for effective vitamin dietary patterns.
METHODS: This study included 3518 CKD patients from 2007 to 2018 National Health and Nutrition Examination Survey database. All participants were categorized into four groups based on vitamin intake by K-mean clustering. The data were collected and analyzed from June 2023 to December 2023.
RESULTS: A total of 3518 CKD patients with a mean age of (61.8 ± 16.3) years were included in the study. During a median follow-up of 7.3 years, 137 participants died of cancer. In the multivariate adjusted cox proportional hazards model for single vitamin intake, vitamin E Q4 intake (reference Q1) reduced cancer mortality (HR (95% CI) = 0.45 (0.24-0.87), P = 0.018). Further plotting of the restricted cubic spline curve revealed a linearly decreasing relationship between vitamin E intake and cancer mortality (Poverall = 0.010 Pnon-linear = 0.163). In the multivariate adjusted cox proportional hazards model for multivitamin co-intake, the vitamin C/K intake group reduced cancer mortality compared to the low vitamin intake group (HR (95% CI) = 0.42 (0.20-0.88), P = 0.022).
CONCLUSION: Increased vitamin C intake was independently associated with reduced cancer risk in CKD patients, and a vitamin dietary pattern with high vitamin C/K intake was also effective in reducing cancer risk.
Safety and effectiveness of SIMPONI ARIA for active polyarticular juvenile idiopathic arthritis and PsA have been established in pediatric patients 2 years and older.

Use of SIMPONI ARIA in these age groups is supported by evidence from adequate and well-controlled studies of SIMPONI ARIA in adults with RA and PsA, pharmacokinetic data from adult patients with RA and PsA and pediatric patients with JIA with active polyarthritis, and safety data from a clinical study in 127 pediatric patients 2 to < 18 years of age with JIA with active polyarthritis. The observed pre-dose (trough) concentrations are generally comparable between adults with RA and PsA and pediatric patients with JIA with active polyarthritis, and the PK exposure is expected to be comparable between adult PsA and pediatric patients with PsA [see Adverse Reactions (6.1), Clinical Pharmacology (12.3)and Clinical Studies (14.2, 14.4)] . 

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with golimumab and other TNF-blocking agents [see Warnings and Precautions (5.2)]. 

The safety and effectiveness in pediatric patients below the age of 2 years have not been established in pJIA or in PsA. The safety and effectiveness of SIMPONI ARIA in pediatric patients with conditions other than pJIA and PsA have not been established.
A number of conditions and factors can cause the transformation of normal cells in the body into malignant tissue by changing the normal functions of a wide range of regulatory, apoptotic, and signal transduction pathways. Despite the current deficiency in fully understanding the mechanism of cancer action accurately and clearly, numerous genes and proteins that are causally involved in the initiation, progression, and metastasis of cancer have been identified. But due to the lack of space and the abundance of details on this complex topic, we have emphasized here more recent advances in our understanding of the principles implied tumor cell transformation, development, invasion, angiogenesis, and metastasis. Inhibition of angiogenesis is a significant strategy for the treatment of various solid tumors, that essentially depend on cutting or at least limiting the supply of blood to micro-regions of tumors, leading to pan-hypoxia and pan-necrosis inside solid tumor tissues. Researchers have continued to enhance the efficiency of anti-angiogenic drugs over the past two decades, to identify their potential in the drug interaction, and to discover reasonable interpretations for possible resistance to treatment. In this review, we have discussed an overview of cancer history and recent methods use in cancer therapy, focusing on anti-angiogenic inhibitors targeting angiogenesis formation. Further, this review has explained the molecular mechanism of action of these anti-angiogenic inhibitors in various tumor types and their limitations use. In addition, we described the synergistic mechanisms of immunotherapy and anti-angiogenic therapy and summarizes current clinical trials of these combinations. Many phase III trials found that combining immunotherapy and anti-angiogenic therapy improved survival. Therefore, targeting the source supply of cancer cells to grow and spread with new anti-angiogenic agents in combination with different conventional therapy is a novel method to reduce cancer progression. The aim of this paper is to overview the varying concepts of cancer focusing on mechanisms involved in tumor angiogenesis and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.
The study is a randomized, single-blinded (blinded to volunteers) placebo-controlled Phase 1 clinical trial in healthy adult volunteers designed to evaluate the safety and reactogenicity of a new malaria blood stage vaccine candidate, and to elucidate the immunogenicity of the antigen, AMA1-C1, formulated on Alhydrogel \[R\]. The trial will last 42 weeks. Volunteers will be recruited and screened, and those determined to be eligible will be enrolled in the study, based on the inclusion and exclusion criteria described in Section 4.0 in this protocol. After providing written informed consent the volunteers will be enrolled and randomly allocated to receive 80 microgram dose of AMA1-C1 formulated on Alhydrogel \[R\] (12 volunteers) or Alhydrogel \[R\] alone (6 volunteers) at 0, 1 and 2 months. After each injection, volunteers will be observed for 60 minutes for immediate reactions. Volunteers will return to the clinic on study days 1, 3, 7, and 14 following each injection for clinical assessment and collection of blood samples for evaluation of immune responses. Leukaphereses will be performed 7 days after the third vaccination to obtain peripheral blood mononuclear cells for B and T cell studies. Safety data for the cohort up to and including follow up day 14 after the first, second and third injection will be available for review by the Medical Monitor.

Immunogenicity of the vaccine will be assessed by standardized assays for antibody levels against AMA1-3D7 and AMA1-FVO, and an in vitro growth inhibition assay (GIA). The cellular basis of the immune responses will be evaluated by enumeration of relevant B and T cell subpopulations, including total and antigen-specific naive, memory and effector subpopulations specific for the antigens. The frequencies of B and T cells specific for the vaccine antigens in the group that received AMA1-C1/ Alhydrogel \[R\] will be compared to those in the group receiving Alhydrogel \[R\] alone. The total and antigen-specific cell frequencies in pre-immune (day 0) samples will serve as additional negative controls for the immunization. The goal of the study is to augment previously collected safety data for the 80 microgram antigen dose with a larger cohort, and to study the safety and immunogenicity of an accelerated vaccination schedule.
The windmill drives an alternator (3) via a mechanical drive including a free - wheel system (7). This allows the the windmill to drive the alternator but not vice - versa. The alternator drives a DC generator (4), as part of an AC/DC converter (2) which in turn acts as a charging source for battery banks (5). Separate circuits provide speed regulation (11) for the DC generator and charging level (12) for the batteries. When win d speed is insufficient to drive the alternator the battery bank drives a stand-by generator (14) which is automatically switched (8) into the supply network (6) instead of the directly driven generator (3). Similarly when conditions require it the DC part of the convertor drives the alternator.
At the time of surgery, the cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as the test group.
This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
The present invention relates to a composition for preventing or treating obesity, comprising a mixed extract from twig of Cinnamomum cassia. More particularly, provided are a pharmaceutical composition for preventing or treating obesity, comprising a mixed extract from twig of Cinnamomum cassia and Moutan Cortex Radicis, a health functional food and a feed composition for preventing or treating obesity, which contains the pharmaceutical composition, and a method for preventing or treating obesity. The method comprises a step of administering the pharmaceutical composition to an individual excluding a human. The mixed extract from twig of Cinnamomum cassia and Moutan Cortex Radicis of the present invention can suppress the intestinal absorption of fat, which causes obesity, and weight gain even upon a single dosage. When administered for a long time, the mixed extract can lower blood lipid levels, reduce adipose tissues in weight and size, effectively inhibit accumulation of lipids in hepatic tissues, and completely overcome fatal side effects of Xenical, such as frequent diarrhea, etc. Hence, the mixed extract can be widely applicable in the development of pharmaceutical compositions and functional foods for preventing or treating obesity.
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) was traditionally limited by high restenosis rates. Coronary stenting using bare metal stents significantly decreases restenosis in CTO compared to balloon angioplasty alone, but restenosis rates still reach 32-55%. In 200 patients with CTO, randomized in the PRISON I study we demonstrated a restenosis rate of 22% after bare metal stent (BMS) implantation as compared with 33% after conventional balloon angioplasty. During the past few years, sirolimus (rapamycin), a cytostatic macrocyclic lactone with anti-inflammatory and antiproliferative properties, delivered from a polymer-encapsulated stent was shown to almost eliminate the risk of restenosis in selected groups of patients. The drug zotarolimus (ABT-578), a sirolimus analogue, is designed to inhibit the cellular process that leads to restenosis. In the PRISON II study we have randomized 200 patients with CTO to either BMS implantation or sirolimus-eluting stent implantation and we demonstrated a reduction of in-stent binary restenosis from 36% to 7% and in-segment binary restenosis rates from 41% to 11% in favour of the sirolimus eluting stent. However, no data are available on direct comparison of the clinical efficacy, safety, and angiographic outcome of particular drug-eluting stents in patients with CTO and there may be differences between various drug-eluting stents. The PRISON III study is designed to address this issue and provide information about two different drug-eluting stents. It is a prospective randomized, single blinded trial comparing the relative safety, clinical efficacy and angiographic outcomes of sirolimus and zotarolimus-eluting stents in patients undergoing successful recanalization of CTO.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of treating and preventing various diseases caused by infection with Helicobacter pylori by including a quinolone derivative as an active ingredient. SOLUTION: This medicine contains a 2-(2-nonenyl)-3-methyl-4(1H)-quinolone derivative of the formula (R1 is H or OH) or a salt thereof as an active ingredient. The compound has a cis isomer, a trans isomer or a tautomeric isomer because having a double bond. The daily dose thereof is 0.1-500 mg/adult in the case of an oral administration, and 0.01-100 mg/adult in the case of parenteral administration and administered by dividing into one or several times. The medicine is effective for prevention (including relapse prevention) and treatment of peptic ulcer (e.g. gastric and duodenal ulcer), inflammation (e.g. acute or chronic gastritis and duodenitis), disease of the upper part of digestive tract such as gastric cancer, MALT(mucosa-associated lymphoid tissue) lymphoma, chronic cardiac disease, etc.
A randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of MCDGs. Twenty-eight healthy male and female subjects aged 21-29 years with normal body weight \[18.5 kg/m\^2 ≤ body mass index (BMI) \< 25 kg/m\^2\] were recruited. The subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. On the first visit, the participants were randomly assigned to consume a test or placebo product \[test product: muffins containing MCDG oil (MCDG muffin); placebo product: muffins containing LCT oil (LCT muffin)\] and ingested the assigned product. On the second visit, the participants consumed the other product that they did not eat on the first visit. On both visit day, the 6-hr meal tolerance test was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (2, 3, 4, and 6 hr) of the products.
This is a double blinded, two arm study, comprising a sham laser and a treatment laser. The sham laser emits approximately 1/1000 the energy of the treatment laser.

It is presumed that pain relief from the treatment laser is achieved by exhausting the release of neurotransmitters from the SPG following laser stimulation. Subjects will be treated and subsequently queried at time intervals for their self-assessment of pain score (VAS). The time intervals include queries at 5 minutes through 2 hours post treatment. Subjects will be further contacted 24 hours and one month post treatment. Adverse events will be monitored and recorded.
<P>PROBLEM TO BE SOLVED: To integrally manage a variety of information related to medical treatment to improve quality of medical practice.  <P>SOLUTION: In this medical information management system 1, a medical information management server 10 stores medical information including patient information, medical supply information and a treatment protocol to integrally manage the prescribed information related to the medical practice. Accordingly, by accessing to the medical information management server 10, the information useful to execute the medical practice can be easily acquired to improve the quality of the medical practice. The information stored in the medical information management server 10 is sequentially updated every time a patient has treatment or the like, every time the medical supply is used, or every time the treatment or the like is executed. Accordingly, the information stored in the medical information management server 10 always becomes latest to further improve the quality of the medical practice.  <P>COPYRIGHT: (C)2004,JPO
The Malmö Diet and Cancer (MDC) study is a population based prospective cohort study. People were enrolled into the cohort between 1991 and 1996, and eligible participants were men born between 1923 and 1945 and women born between 1923 and 1950, living in the city of Malmö. Swedish reading and writing skills were required. People were 44-73 years at enrolment. The data collection was done both using questionnaires and interviews, including data on dietary habits, socio-economics, medical history and lifestyle factors. The total number of study subjects were 28,098.
Agent having immunoregulatory properties, especially inhibitory activity against in-vivo development of those organisms or cells which are capable of secreting or freeing in vivo "immuno-repulsive substances", especially low molecular weight antiinflammatories, contains active constituents of higher molecular weight, having in their structures several groups respectively derived from low molecular weight immuno-repulsive substances of the type which pathogenic cells or organisms of the type in question are capable of secreting or freeing either in the host organism or in vitro culture medium; the number of these groups being sufficient to give the active constituents a sufficient molecular weight so as to make them immunogenic. Usually the higher molecular weight active constituents are polymers of the "immuno-repulsive substances." "Immuno-repulsive substances" are those cpds. which are capable of blocking the normal immune defence mechanisms of the host. Immunoregulatory substances which reinforce the immune defence mechanism of the host against pathogens. The substances may be used therapeutically to inhibit the proliferation of metastases and malignant tumour cells or to avoid the development of microorganisms or parasites which inhibit the immune defence mechanism of the host. The agent may also be associated with (opt. co-crosslinked) the active constituents of specific vaccines, which are only weakly effective, so as to reinforce their activity. The substances are usually administered parentally, orally or rectally in doses of 5-10 mg/kg. The substances may also be used as reagents e.g. as reference standards in the testing of substances which inhibit malignant tumours, pathogenic microorganisms, parasites.